Here’s what you should know:
1. Sanovas is hoping the move will increase the company’s Chinese sales.
2. The venture capital fund will invest $75 million in the development of Sanovas’ surgical imaging, thoracic oncology, interventional pulmonology, ENT, ophthalmology and biosciences platforms.
3. Suzhou City Mayor Xiang Wang said in a release, “We respect Sanovas and the company’s approach to developing innovative technologies and improving treatments in medicine for so many.”
More articles on improving health:
Mississippi Valley Health CEO Michael Patterson on the most pressing issues facing ASCs today and in the future
Surgery Partners merges subsidiary, prices $370M senior note offering: 4 things to know
SurgCenter Development completes 20,000th TJR; Medical Facilities Corp. shares fall 5% since Britt Reynolds’ departure & more
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
